[The value of serum tissue polypeptide specific antigen TPS concentration in therapeutic monitoring of patients with epithelial malignant ovarian neoplasms].
METHODS
The aim of this study was compare the concentrations TPS and CA 125 in serum 37 patients with ovarian carcinoma in order to evaluate the usefulness of markers in monitoring therapy.


METHODS
The concentrations of TPS and CA 125 were determined prior to surgery, 1 week after surgery, prior chemotherapy, after 3 and 6 course chemotherapy next every 3 months for the first year and every 6 month for the next 2 years.


RESULTS
The concentration of TPS decreased above cutoff values in all patients with remission after 3 course chemotherapy, CA 125 after 6 course chemotherapy. In patients with remission the increase of TPS preceded 3 to 12 months, of CA 125 1 to 3 month the reoccurence of the disease. In of patients with progressive disease the TPS levels decreased during therapy and next rise.


CONCLUSIONS
The current observations demonstrate that serial measurements of TPS appear to be useful for the evaluation of therapy and monitoring of patients.
Zakrzewska
I
I
Zakładu Laboratoryjnej Diagnostyki Klinicznej, Akademii Medycznej w Białymstoku.
Borawska
R
R
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D008991:Monitoring, Physiologic; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000628:therapy; D010455:Peptides / Q000097:blood*; D011184:Postoperative Period; D012074:Remission Induction
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D010455:Peptides; C089984:tissue polypeptide specific antigen; D003520:Cyclophosphamide; D002945:Cisplatin
Wartość oznaczania stezenia specyficznego polipeptydowego antygenu TPS w surowicy w monitorowaniu leczenia chorych na nabłonkowe złośliwe nowotwory jajnika.